Chegg drops more than 40% after saying ChatGPT is killing its business

Market Insider

James Tahaney loads textbooks on to a pallet in preparation for shipping at the Chegg warehouse in Shepherdsville, Kentucky, April 29, 2010.
John Sommers II | Bloomberg | Getty Images

Chegg shares tumbled after the online education company said ChatGPT is hurting growth.

“In the first part of the year, we saw no noticeable impact from ChatGPT on our new account growth and we were meeting expectations on new sign-ups,” CEO Dan Rosensweig said during the earnings call Tuesday evening. “However, since March we saw a significant spike in student interest in ChatGPT. We now believe it’s having an impact on our new customer growth rate.”

The company, which provides homework assistance and online tutoring, said revenue would be between $175 million to $178 million this quarter, far below the analyst consensus estimate from FactSet of $193.6 million.

Chegg shares were last down 46% to $9.50 in premarket trading Wednesday, set to add to a 30% decline already this year.

Stock Chart IconStock chart icon

Chegg shares 1-day

Otherwise, Chegg beat first-quarter expectations on the top and bottom lines. The online education firm reported first-quarter earnings of 27 cents per share ex-items on revenue of $188 million. Analysts polled by Refinitiv had expected per-share earnings of 26 cents per share on revenue of $185 million.

Following the results, Jefferies downgraded the stock to hold from buy, citing the threat artificial intelligence poses on the stock. The Wall Street firm cut its price target to $11 from $25, implying shares could fall more than 35% from Monday’s close. 

Meanwhile, Morgan Stanley analyst Josh Baer slashed his price target to $12 from $18, implying a 30% fall. The analyst said that AI “completely overshadowed” the results,

Articles You May Like

AI’s Dark Horse Could Become Its Crown Jewel Under Trump
5 Stocks to Buy on a Trump Victory 
Market Watch: How Trump’s Tariff Strategy Could Reshape This Rally
Hedge funds performed better under Democratic presidents than Republican ones, history shows
Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value